Waghorn Tania S, Miller Chris M, Leathwick Dave M
AgResearch Grasslands, Private Bag 11008, Tennent Drive, Palmerston North, 4442, New Zealand.
AgResearch Grasslands, Private Bag 11008, Tennent Drive, Palmerston North, 4442, New Zealand.
Vet Parasitol. 2016 Oct 15;229:139-143. doi: 10.1016/j.vetpar.2016.10.011.
Six suspected cases of ivermectin resistance in Ostertagia spp. in cattle were investigated after routine anthelmintic efficacy testing on commercial farms. On four farms a comprehensive faecal egg count reduction test (FECRT) was undertaken using oral formulations of ivermectin (0.2mg/kg), albendazole (10mg/kg) and levamisole (7.5mg/kg) while on two farms only ivermectin was tested. The proportions of Ostertagia spp. in the untreated control and post-treatment larval cultures were used to apportion egg counts to genera and determine efficacy against this genus. Isolates of Ostertagia spp. recovered from three of the farms were each used to infect 18 six month old calves. The efficacy of oral formulations of ivermectin and moxidectin, both at 0.2mg/kg, was determined against each isolate by slaughter and worm count. The efficacy of ivermectin against Ostertagia spp., based on differentiated FECRT for each of the farms varied from 0% to 88%. The efficacy of ivermectin based on worm counts in the slaughter trial varied from 13% to 75% but moxidectin was >99% effective against all isolates. In addition, in the FECRT albendazole, at a dose rate of 10mg/kg, failed to achieve 95% efficacy against Ostertagia spp. on two farms (82% and 85%). Levamisole consistently failed to achieve 95% efficacy against Ostertagia spp. which is consistent with its known lesser efficacy against this parasite. These results confirm the presence of macrocyclic lactone resistant O. ostertagi in cattle in New Zealand and the likely presence of dual resistance, to macrocyclic lactones and albendazole, in some isolates. Resistant populations of this highly pathogenic parasite are probably not uncommon in New Zealand and pose a significant threat to animal production and welfare in the future.
在商业农场对牛进行常规驱虫药疗效测试后,对6例疑似牛奥斯特他线虫对伊维菌素耐药的病例展开了调查。在4个农场,使用伊维菌素(0.2mg/kg)、阿苯达唑(10mg/kg)和左旋咪唑(7.5mg/kg)口服制剂进行了全面的粪便虫卵计数减少试验(FECRT),而在2个农场仅对伊维菌素进行了测试。未处理对照和治疗后幼虫培养物中奥斯特他线虫属的比例用于将虫卵计数分配到各个属,并确定对该属的疗效。从3个农场回收的奥斯特他线虫属分离株分别用于感染18头6月龄犊牛。通过屠宰和蠕虫计数确定了0.2mg/kg的伊维菌素和莫昔克丁口服制剂对每个分离株的疗效。基于各农场区分性FECRT,伊维菌素对奥斯特他线虫属的疗效在0%至88%之间。基于屠宰试验中的蠕虫计数,伊维菌素的疗效在13%至75%之间,但莫昔克丁对所有分离株的有效性均>99%。此外,在FECRT中,剂量率为10mg/kg的阿苯达唑在2个农场未能对奥斯特他线虫属达到95%的疗效(分别为82%和85%)。左旋咪唑始终未能对奥斯特他线虫属达到95%的疗效,这与其已知的对该寄生虫较低的疗效一致。这些结果证实了新西兰牛群中存在对大环内酯类耐药的奥氏奥斯特他线虫,并且在一些分离株中可能存在对大环内酯类和阿苯达唑的双重耐药性。这种高致病性寄生虫的耐药种群在新西兰可能并不罕见,未来对动物生产和福利构成重大威胁。